EZH2 is an independent biomarker of breast cancer risk in normal breast samples, helping to determine the malignancy risk in benign biopsies.4 The investigation of such possibility in benign salivary tumors deserves attention. This evidence concerns the gene EZH2 and breast carcinoma.